Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $12.26, but opened at $12.61. Generate Biomedicines shares last traded at $12.5120, with a volume of 796,486 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GENB. Wall Street Zen upgraded Generate Biomedicines from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Generate Biomedicines in a report on Monday, October 5th. Finally, Weiss Ratings upgraded Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 25th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.40.

Generate Biomedicines Stock Performance

The stock has a market capitalization of $1.59 billion and a PE ratio of -7.77. The company’s fifty day simple moving average is $15.52 and its two-hundred day simple moving average is $14.43.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. Sell-side analysts forecast that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GENB. State Street Corp acquired a new stake in Generate Biomedicines during the 2nd quarter valued at $8,883,000. The Manufacturers Life Insurance Company acquired a new position in shares of Generate Biomedicines in the second quarter worth $1,431,000. Squarepoint Ops LLC acquired a new position in shares of Generate Biomedicines in the second quarter worth $530,000. AXQ Capital LP purchased a new stake in shares of Generate Biomedicines in the second quarter valued at $218,000. Finally, Braidwell LP purchased a new stake in shares of Generate Biomedicines in the second quarter valued at $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.